A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
Successful cancer immune therapy correlates with a T cell-inflamed tumour microenvironment. Authors show here that co-administration of a self-adjuvanting protein vaccine and an antigen-expressing oncolytic virus in an optimised regimen strongly enhances T cell immunogenicity and may turn non-inflam...
Guardado en:
Autores principales: | Krishna Das, Elodie Belnoue, Matteo Rossi, Tamara Hofer, Sarah Danklmaier, Tobias Nolden, Liesa-Marie Schreiber, Katharina Angerer, Janine Kimpel, Sandra Hoegler, Bart Spiesschaert, Lukas Kenner, Dorothee von Laer, Knut Elbers, Madiha Derouazi, Guido Wollmann |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6a4885a11bbe41c6aef5c595a4d1525a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
por: D. G. Roy, et al.
Publicado: (2021) -
Chemogenetic ON and OFF switches for RNA virus replication
por: E. Heilmann, et al.
Publicado: (2021) -
Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants.
por: André Volland, et al.
Publicado: (2021) -
SELECTED ASPECTS OF ALLO- AND XENOGRAFT MODEL APPLICATIONS FOR DEVELOPING NOVEL ANTI-CANCER VACCINES AND ONCOLYTIC VIRUSES
por: T. S. Nepomnyashchikh, et al.
Publicado: (2019) -
Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis
por: Amanda W. K. AuYeung, et al.
Publicado: (2021)